<DOC>
	<DOC>NCT00478049</DOC>
	<brief_summary>This is a randomized, open-label, parallel group, phase III, multicenter, regional study. The total number of patients expected to be exposed to study procedures is approximately 150 patients will be recruited by investigational sites throughout the Asia Pacific region that have expertise in treating patients with NSCLC.</brief_summary>
	<brief_title>Iressa as Second Line Therapy in Advanced NSCLC-Asia</brief_title>
	<detailed_description />
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histologically or cytologically confirmed nonsmall cell bronchogenic carcinoma: adenocarcinoma (including bronchoalveolar), squamous cell carcinoma, large cell carcinoma or mixed (adenocarcinoma and squamous) or undifferentiated carcinoma. WHO Performance status 02 NSCLC locally advanced (Stage IIIB) or metastatic (stage IV) disease, not amenable to curative surgery or radiotherapy Life expectancy of 12 weeks. ALT/AST: &gt;2.5x ULRR if no demonstrable liver metastases or greater than 5 x ULRR in the presence of liver. Inadequate bone marrow function; Absolute neutrophil count: &lt;1.5 x 109/L, Platelets: &lt; 100 x 109/L Other coexisting malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma of skin or cervical cancer in situ</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
</DOC>